Peptide Science Forbes

Peptide Science Forbes: The Boom, The Risks, and The Next Medical Frontier

From Hollywood to Sydney, peptides are having their moment. In wellness and biohacking circles, injectable peptides like BPC-157, TB-500, and GHK-Cu are being touted as cure-alls for tissue repair, skin quality, gut health, and hair growth. Meanwhile, Peptide Science Forbes therapeutics market generated US$1.625 billion in revenue in 2024 and is expected to reach US$3.33 billion by 2030.

But beneath the capital chasing and social media frenzy, a fundamental question is emerging: What exactly are we injecting into our bodies?

What Are Peptides – The Body’s Source Code

To understand the frenzy, you first need to understand what peptides are. Peptide Science Forbes are short chains of amino acids – the precursors to proteins. If DNA is the body’s blueprint and proteins are the workers and machines, then peptides are the parts being assembled into those machines. They act as signalling molecules, regulating everything from hormone secretion and inflammation to metabolism and tissue repair.

For decades, our understanding of Peptide Science Forbes was constrained by a core problem: the protein folding problem. Knowing the amino acid sequence (one-dimensional information) doesn’t tell you how a protein will ultimately fold into its three-dimensional structure – and structure determines function. In 2020, Google DeepMind’s AlphaFold effectively solved this problem that had puzzled biology for 50 years. In 2024, the breakthrough was recognised with the Nobel Prize in Chemistry.

This means humanity now has the ability to “read” the operating system of living organisms – and that is the true starting point of the peptide science revolution.

Australia’s Peptide Boom: Two Faces

In Australia, this boom presents two very different faces.

One face is serious science and commerce. Melbourne-based biotech Aravax has spent more than a decade breaking peanut proteins down into peptide fragments, screening for specific peptides that can interact with immune T-cells without triggering the allergic antibody IgE. The result is PVX108, a therapy that could fundamentally change peanut allergy treatment. The product has completed Phase 1 safety trials and is now in Phase 2 trials in both Australia and the United States. The global peanut allergy treatment market is projected to reach US$4 billion by 2027.

Another Australian company, Tetratherix, has built a $255 million ASX-listed company around a single injectable polymer. That same material is now being used in everything from dental surgery to prostate cancer treatment and GLP-1 delivery. The company recently signed a $3 million-a-year deal with Superpower Health to explore nasal delivery of peptides and metabolic compounds.

On the consumer side, Australian brand Vida Glow has built its success on marine collagen peptides. In Australia, the company has experienced 40% year-on-year growth. Its tripeptide marine collagen product has been clinically shown to reduce wrinkles.

The other face is the grey market and risk. Driven by social media and online communities, consumers are bypassing regulatory systems and buying injectable peptides from overseas. The Therapeutic Goods Administration (TGA) has warned consumers about the risks of importing and using unapproved peptide products.

“Promising Biology Is Not Proven Clinical Benefit”

In a commentary published by Forbes Australia, Dr Sophia Moscovis – who has spent more than 20 years across biomedical research, clinical trials, and pharmaceutical drug development – issued a core warning: “Promising biology is not proven clinical benefit”.

She points out that GLP-1 receptor agonists, including semaglutide (Ozempic), underwent extensive randomised controlled trials and long-term safety evaluation before approval. But most peptides circulating in the wellness market have not followed this path.

Independent testing has found troubling problems. According to ACS Peptide Testing Labs, 17 per cent of peptide samples analysed contained detectable levels of heavy metals including lead, cadmium, and mercury. Independent testing of grey-market peptides has also found significant variability in Peptide Science Forbes content versus label claims, endotoxin contamination from poor manufacturing, and in some cases, entirely wrong compounds in the vial.

Even more concerning are the biological unknowns. Several widely used peptides promote angiogenesis – the formation of new blood vessels – which is central to their appeal for tissue repair. But angiogenesis is also how tumours sustain themselves and metastasise. Dr Moscovis writes: “This does not mean these peptides cause cancer. But within any large population using these compounds, some will have early undiagnosed malignancies. Whether pro-angiogenic peptides could accelerate progression in those individuals has not been studied”.

The TGA has now issued a joint statement with Australia’s Chief Medical Officer expressing concerns about the public health risks associated with unapproved peptide products. Serious adverse effects reported include liver damage, severe allergic reactions requiring hospitalisation, and inflammation.

Who Is Qualified to Give Advice on Peptides?

As peptides enter the mainstream health discussion, a new question emerges: who is actually qualified to give advice on peptides?

In most cases, prescription peptides are restricted to licensed medical practitioners. But the reality is far more complex. Some peptides are prescribed by doctors through regulated channels; others are compounded by pharmacies operating at the edges of traditional medicine; and a growing number come from influencers, biohackers, and wellness personalities – many of whom are sharing personal experience rather than practising within a clinical scope.

“Peptides exist in a grey zone – part clinical, part experimental, and increasingly part content,” as one observer put it. Regulation hasn’t fully caught up: some peptides are approved for specific uses, some are used off-label, and others are sold as “for research use only” – even as they’re being used in humans.

The TGA has ramped up enforcement. In the 2024–25 financial year, the agency requested the removal of more than 13,700 online advertisements, many involving wellness and beauty therapeutic goods. The TGA received over 32,000 alleged non-compliance reports. One individual in Victoria was fined $3,756 for the alleged unlawful importation of a peptide; another received three infringement notices totalling $11,268. A person in New South Wales was issued 27 infringement notices and fined more than $100,000 for supplying the unapproved peptide melanotan II.

Yet despite the crackdown, the online marketplace is thriving. Medscape News Australia counted 30 online vendors marketing unapproved peptides to Australians. “This is the beginning of the boom, not the peak,” one industry observer told Medscape.

The Regulatory Response and the Path Forward

The TGA has now expanded its priority focus areas to include unapproved peptide products, following increased detection of unlawful importation, supply, and advertising. In May 2026, the TGA seized almost a million units of illicit pharmaceuticals as part of a global police operation that saw 5,700 online sellers shut down.

But regulation is only part of the solution. The future of peptide science depends on three critical factors:

First, evidence. More large-scale, long-term human clinical trials are needed to validate the safety and efficacy of peptides. Most wellness peptides lack this evidence. The contrast with approved therapeutics like GLP-1 receptor agonists – which underwent years of randomised controlled trials – could not be starker.

Second, education. Consumers need to understand the difference between “promising biology” and “proven clinical benefit”. They need to know that the peptides being promoted online are not evaluated for safety, quality, or effectiveness. And they need to understand that the danger includes not just the compounds themselves, but what else may be in the vial.

Third, innovation. Australia has world-class peptide science. The Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, based at the University of Sydney, is conducting cutting-edge research. Researchers like Professor Lara Malins at ANU are working on peptide-drug conjugates as promising therapeutic modalities. Companies like Aravax and Tetratherix are demonstrating that Australian peptide science can compete on the world stage.

The Bottom Line

Peptides represent one of the most exciting frontiers in modern medicine. The science is real, the potential is enormous, and Australian researchers and companies are at the forefront.

But the current peptide boom – driven by social media, wellness culture, and a hunger for “health optimisation” – is running ahead of the evidence. Consumers are injecting compounds that haven’t been properly studied in humans, sourced from suppliers who aren’t subject to quality controls, and promoted by influencers who aren’t qualified to give medical advice.

The TGA and Australia’s Chief Medical Officer have now jointly warned that unapproved peptide products pose a “significant” public health risk. The agency has strengthened its compliance focus, issued infringement notices, and seized illicit products.

But regulation alone cannot solve the problem. The peptide industry – both its legitimate and grey-market wings – needs more evidence, better education, and a clearer regulatory framework. Consumers need to ask harder questions about what they’re injecting and why. And the medical community needs to engage more actively with the peptide conversation, rather than leaving it to influencers and biohackers.

As Dr Moscovis writes: “The pathway from preclinical signal to human evidence to regulatory approval exists for good reason”. That pathway exists to protect patients. And in the rush to embrace the next big thing in wellness, we would do well not to forget it.

The peptide boom is only just beginning. Whether it becomes a medical revolution or a public health crisis will depend on the choices we make – as consumers, as clinicians, and as a society – about how we handle the science, the regulation, and the hype.